Terms: = Liver cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Treatment
61 results:
1. Discovery of novel fgfr4 inhibitors through a build-up fragment strategy.
Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
[TBL] [Abstract] [Full Text] [Related]
2. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.
Lin K; Xia B; Wang X; He X; Zhou M; Lin Y; Qiao Y; Li R; Chen Q; Li Y; Feng J; Chen T; Chen C; Li X; Zhang H; Lu L; Liu B; Zhang X
J Transl Med; 2024 Apr; 22(1):349. PubMed ID: 38610029
[TBL] [Abstract] [Full Text] [Related]
3. Blocking of fgfr4 signaling by F30 inhibits hepatocellular carcinoma cell proliferation through HMOX1-dependent ferroptosis pathway.
Huang F; Shi X; Hu M; Yan H; Li X; Ding Y; Zheng X; Cai X; Dai S; Xia Q; Cai Y
Eur J Pharmacol; 2024 May; 970():176493. PubMed ID: 38484925
[TBL] [Abstract] [Full Text] [Related]
4. FGF19/fgfr4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
[TBL] [Abstract] [Full Text] [Related]
5. Insight into the design of fgfr4 selective inhibitors in cancer therapy: Prospects and challenges.
Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
[TBL] [Abstract] [Full Text] [Related]
6. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating fgfr4 expression.
Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
[TBL] [Abstract] [Full Text] [Related]
7. EGFR Inhibition Overcomes Resistance to fgfr4 Inhibition and Potentiates fgfr4 Inhibitor Therapy in Hepatocellular Carcinoma.
Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
[TBL] [Abstract] [Full Text] [Related]
8. Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel fgfr4 inhibitors for the treatment of colorectal cancer.
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2023 Nov; 259():115703. PubMed ID: 37556948
[TBL] [Abstract] [Full Text] [Related]
9. Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of fgfr4 in wild-type and gatekeeper mutants.
Yang Y; He X; Li Z; Ran K; Wang N; Zhao L; Liu Z; Zeng J; Chang B; Feng Q; Zhang Q; Yu L
Eur J Med Chem; 2023 Oct; 258():115628. PubMed ID: 37437349
[TBL] [Abstract] [Full Text] [Related]
10. Small Extracellular Vesicle-Derived vWF Induces a Positive Feedback Loop between Tumor and Endothelial Cells to Promote Angiogenesis and Metastasis in Hepatocellular Carcinoma.
Wong SWK; Tey SK; Mao X; Fung HL; Xiao ZJ; Wong DKH; Mak LY; Yuen MF; Ng IO; Yun JP; Gao Y; Yam JWP
Adv Sci (Weinh); 2023 Sep; 10(26):e2302677. PubMed ID: 37387563
[TBL] [Abstract] [Full Text] [Related]
11. fgfr4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
[TBL] [Abstract] [Full Text] [Related]
12. FGF19/fgfr4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract] [Full Text] [Related]
13. First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.
Harding JJ; Jungels C; Machiels JP; Smith DC; Walker C; Ji T; Jiang P; Li X; Asatiani E; Van Cutsem E; Abou-Alfa GK
Target Oncol; 2023 Mar; 18(2):181-193. PubMed ID: 36787089
[TBL] [Abstract] [Full Text] [Related]
14. A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma.
Zhou M; Zhu S; Xu C; Liu B; Shen J
Invest New Drugs; 2023 Feb; 41(1):162-167. PubMed ID: 36763233
[TBL] [Abstract] [Full Text] [Related]
15. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979
[TBL] [Abstract] [Full Text] [Related]
16. Discovery of 2-Amino-7-sulfonyl-7
Xie W; Yang S; Liang L; Wang M; Zuo W; Lei Y; Zhang Y; Tang W; Lu T; Chen Y; Jiang Y
J Med Chem; 2022 Dec; 65(24):16570-16588. PubMed ID: 36480917
[TBL] [Abstract] [Full Text] [Related]
17. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and RAF1 Targets.
Kityania S; Nath R; Nath D; Patra JK; Talukdar AD
Comb Chem High Throughput Screen; 2023; 26(10):1907-1919. PubMed ID: 36321230
[TBL] [Abstract] [Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
[TBL] [Abstract] [Full Text] [Related]
19. FGFR redundancy limits the efficacy of fgfr4-selective inhibitors in hepatocellular carcinoma.
Tao Z; Cui Y; Xu X; Han T
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
[TBL] [Abstract] [Full Text] [Related]
20. Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment.
Wilbaux M; Demanse D; Gu Y; Jullion A; Myers A; Katsanou V; Meille C
CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1122-1134. PubMed ID: 35728123
[TBL] [Abstract] [Full Text] [Related]
[Next]
